Initiation of Phase 1 clinical trial of GT-02287 in Australia expected in H2 2023. Presentation of two posters with new in vivo data at the upcoming International Congress of Parkinson’s Disease and Movement Disorders being held August 27-31, in Copenhagen, Denmark. Neuroprotective effect of GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase, leads to a significant reduction of plasma neurofilament light chain levels and improvement in behavioral deficits in a mouse model of GBA1 Parkinson’s disease. GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease. Progression of one of the Company’s oncology programs to lead series selection by the end of 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GANX:
- Gain announces acceptance of late breaking abstract to present on GT-02287
- Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
- Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference